Gabriel Levin, Clinical Fellow at McGill University Health Centre and Director of Oncology at CureLab Oncology, shared a post on LinkedIn:
“Humbled, and grateful to the ESGO scientific and clinical community for the opportunity to present our randomized Phase II trial in platinum-resistant ovarian cancer at the ESGO 2026 Congress in Copenhagen.
Presenting data on novel therapeutic strategies in this challenging disease setting, particularly in a randomized framework, is both a privilege and a responsibility.
The level of engagement, thoughtful questions, and collegial dialogue at ESGO once again reinforced why this community is so impactful. It is inspiring to be part of a global network committed to improving outcomes for women with gynecologic cancers.
Thank you to the investigators, collaborators, patients, and study teams who made this work possible.
A truly outstanding conference in Copenhagen, scientifically rigorous, forward-thinking, and deeply collaborative.“
Other articles about ESGO 2026 on OncoDaily.
